Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure

Nucl Med Commun. 2016 Mar;37(3):283-7. doi: 10.1097/MNM.0000000000000439.

Abstract

Objectives: Radioiodine therapy could be challenging in chronic renal failure patients requiring hemodialysis. The aim of this study was to establish the effects of hemodialysis on elimination of radioiodine from the body in thyroid carcinoma patients with end-stage chronic renal failure and to determine its effects on environmental radiation dose.

Materials and methods: Three end-stage chronic renal failure patients (four cases) diagnosed with differentiated thyroid carcinoma requiring radioiodine therapy were included in our study. Each patient was given 50-75 mCi (1850-2775 MBq) iodine-131 with 50% dose reduction. Dose rate measurement was performed at the 2nd, 24th, and 48th hour (immediately before and after hemodialysis) after radioiodine administration. The Geiger-Müller probe was held at 1 m distance at the level of the midpoint of the thorax for the dose rate measurement.

Results and conclusion: The effective half-life of iodine-131 for three patients was found to be 44 h. In conclusion, the amount of radioiodine excreted per hemodialysis session was calculated to be 51.25%.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Humans
  • Iodine Radioisotopes / pharmacokinetics*
  • Iodine Radioisotopes / therapeutic use*
  • Iodine Radioisotopes / urine
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / therapy*
  • Kinetics
  • Male
  • Middle Aged
  • Renal Dialysis*
  • Thyroid Neoplasms / complications*
  • Thyroid Neoplasms / metabolism*
  • Thyroid Neoplasms / radiotherapy

Substances

  • Iodine Radioisotopes